Results 221 to 230 of about 315,994 (289)

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal   +5 more
wiley   +1 more source

Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cutaneous lupus erythematosus (CLE) is an inflammatory skin manifestation of systemic lupus erythematosus. Type I interferons (IFNs) promote inflammatory responses and are elevated in CLE lesions. We recently reported that CLE lesions are frequently colonized with Staphylococcus aureus.
Lisa Abernathy‐Close   +9 more
wiley   +1 more source

Endogenous Retroelement Activation is Implicated in Interferon‐α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Endogenous retroelements (EREs) stimulate type 1 interferon (IFN‐I) production but have not been explored as potential interferonogenic triggers in rheumatoid arthritis (RA). We investigated ERE expression in early RA (eRA), a period in which IFN‐I levels are increased.
Faye A. H. Cooles   +12 more
wiley   +1 more source

Changes in Descending Pain Modulation During Anti–Tumor Necrosis Factor Therapy: A Prospective Study in Rheumatoid Arthritis and Spondyloarthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective In rheumatoid arthritis (RA) and spondyloarthritis (SpA), managing persistent pain remains challenging. Little is known regarding impaired pain pathways in these patients and the impact of biologic disease‐modifying antirheumatic drugs (bDMARDs).
Anne‐Priscille Trouvin   +9 more
wiley   +1 more source

Association of Synovial Innate Immune Exhaustion With Worse Pain in Knee Osteoarthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Uncontrolled pain remains a major clinical challenge in the management of knee osteoarthritis (OA), the most common disabling joint disease. Worse pain is associated with synovial innate immune cell infiltration (synovitis), but the role of innate immune‐regulatory cells in pain is unknown. Our objective was to identify synovial innate immune
Holly T. Philpott   +14 more
wiley   +1 more source

Metabolic Stress Expands Polyfunctional, Proinflammatory Th17 Cells in Patients With Psoriatic Arthritis for Whom There is Interleukin‐23–Independent Interleukin‐17 Production

open access: yesArthritis &Rheumatology, EarlyView.
Objective Genetic associations and blockade of the interleukin (IL)‐23/IL‐17 axis with monoclonal antibodies support a role for this pathway in patients with psoriatic arthritis (PsA). This study examines the requirement of IL‐23 for IL‐17 production and the role of the metabolic microenvironment in the expansion of Th17‐derived cells in patients with ...
Carmel B. Stober   +4 more
wiley   +1 more source

Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10‐Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10‐year follow‐up.
Nikolaos Papazoglou   +2 more
wiley   +1 more source

Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin‐1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is a rare but severe autoimmune disease characterized by immune dysregulation, fibrosis, and vasculopathy. Although previous studies have highlighted the presence of functional autoantibodies targeting the angiotensin II receptor type 1 (AT1) and endothelin‐1 type A receptor (ETAR), leading to autoantibody‐mediated ...
Wieke M. van Oostveen   +8 more
wiley   +1 more source

An Immunosenescent CD8+ T Cell Subset in Patients with Axial Spondyloarthritis and Psoriatic Arthritis Links Spontaneous Motility to Telomere Shortening and Dysfunction

open access: yesArthritis &Rheumatology, EarlyView.
Objective A pathogenetic role of CD8+ T lymphocytes in radiographic axial spondyloarthritis (r‐axSpA) and other spondyloarthritis (SpA) is sustained by genome‐wide association studies and by the expansion of public T cell clonotypes in the target tissues.
Giorgia Paldino   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy